lifestyle.successfuldaily.com

Author: IGC Pharma, Inc.

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

April 22, 2026
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

April 14, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

April 8, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease

April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

March 30, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026

March 18, 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research

February 26, 2026
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026